Strategic partnerships Kanyos Bio operates as an antigen-specific immune tolerance platform with collaboration ties to Anokion and Astellas. This indicates a path for co-development, licensing, or strategic alliances for complementary autoimmune indications and regulatory pathways.

Acquisition history Recent news notes Anokion acquired Kanyos Bio, suggesting consolidation and potential transition of programs, IP, and ongoing collaborations. This signals opportunities to engage with the parent and sister entities for portfolio alignment or asset-specific discussions.

Addressable market Focused on type-1 diabetes and celiac disease with disease-modifying, antigen-specific approaches. There is significant market interest in immunotherapies and tolerance technologies, offering avenues for joint ventures, research funding, or early-access programs.

Funding and scale Current revenue under $1M with $27M in funding positions the company for early-stage partnerships and pilot programs. Target partnerships that provide translational support, manufacturing, or clinical development resources to accelerate milestones.

Operating footprint Small company size (11-50 employees) with a tech stack and global collaboration potential. Opportunities exist for service-based engagements (data analytics, regulatory consulting, CRO/CMO partnerships) to complement their development activities.